Influence of 5-Fluorouracil and Folinic Acid on Interleukin-18 Production in Colorectal Cancer Patients

2002 ◽  
Vol 17 (1) ◽  
pp. 63-66 ◽  
Author(s):  
R.A. Merendino ◽  
A. Ruello ◽  
S. Cascinu ◽  
B. Ferlazzo ◽  
A. Bene ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Adjuvant Chemotherapy ◽  
Folinic Acid ◽  
Cancer Patients ◽  
Serum Levels ◽  
Interleukin 18 ◽  
Blood Concentrations ◽  
Healthy Donors ◽  
Before And After ◽  
Colorectal Cancer Patients

Aims and Background This study was carried out to evaluate the IL-18 blood concentrations of operated colorectal cancer patients and their possible variation in response to combination chemotherapy with 5-fluorouracil (5-FU) and folinic acid. Methods IL-18 levels were assayed in sera of 18 healthy donors and 18 surgical colorectal cancer patients before and after adjuvant chemotherapy with 5-fluorouracil and folinic acid. An ELISA kit for human IL-18 was used for the assay. Results Colorectal cancer patients showed significantly higher baseline levels of IL-18 than healthy donors (p<0.005). Furthermore, serum IL-18 levels increased significantly with respect to baseline in patients receiving adjuvant chemotherapy (p<0.005). Conclusions This study suggests that treatment with 5-fluorouracil and folinic acid may provoke an increase in IL-18 serum levels in colorectal cancer patients. This increase may help to explain the efficacy of adjuvant chemotherapy with 5-FU in colorectal cancer.

Influence of 5-fluorouracil and folinic acid on interleukin-18 production in colorectal cancer patients

2002 ◽  
Vol 17 (1) ◽  
pp. 63-66 ◽  
Author(s):  
R.A. Merendino ◽  
A. Ruello ◽  
S. Cascinu ◽  
B. Ferlazzo ◽  
A. Bene ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Folinic Acid ◽  
Cancer Patients ◽  
Interleukin 18 ◽  
Colorectal Cancer Patients

scholarly journals Postoperative Serum Levels of sCD26 for Surveillance in Colorectal Cancer Patients

PLoS ONE ◽  
2014 ◽  
Vol 9 (9) ◽  
pp. e107470 ◽  
Author(s):  
Loretta De Chiara ◽  
Ana M. Rodríguez-Piñeiro ◽  
Oscar J. Cordero ◽  
Lidia Vázquez-Tuñas ◽  
Daniel Ayude ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Cancer Patients ◽  
Serum Levels ◽  
Postoperative Serum ◽  
Colorectal Cancer Patients

Clinical and Socioeconomic Factors that Predict Non-completion of Adjuvant Chemotherapy for Colorectal Cancer in a Rural Cancer Center

2022 ◽  
pp. 000313482110547
Author(s):  
Chelsea Knotts ◽  
Alexandra Van Horn ◽  
Krysta Orminski ◽  
Stephanie Thompson ◽  
Jacob Minor ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Adjuvant Chemotherapy ◽  
Socioeconomic Factors ◽  
Cancer Patients ◽  
Private Insurance ◽  
Stage Ii ◽  
Stage Iii ◽  
Insurance Status ◽  
Complete Treatment ◽  
Colorectal Cancer Patients

Background Previous literature demonstrates correlations between comorbidities and failure to complete adjuvant chemotherapy. Frailty and socioeconomic disparities have also been implicated in affecting cancer treatment outcomes. This study examines the effect of demographics, comorbidities, frailty, and socioeconomic status on chemotherapy completion rates in colorectal cancer patients. Methods This was an observational case-control study using retrospective data from Stage II and III colorectal cancer patients offered chemotherapy between January 01, 2013 and January 01, 2018. Data was obtained using the cancer registry, supplemented with chart review. Patients were divided based on treatment completion and compared with respect to comorbidities, age, Eastern Cooperative Oncology Group (ECOG) score, and insurance status using univariate and multivariate analyses. Results 228 patients were identified: 53 Stage II and 175 Stage III. Of these, 24.5% of Stage II and 30.3% of Stage III patients did not complete chemotherapy. Neither ECOG status nor any comorbidity predicted failure to complete treatment. Those failing to complete chemotherapy were older (64.4 vs 60.8 years, P = .043). Additionally, those with public assistance or self-pay were less likely to complete chemotherapy than those with private insurance ( P = .049). Both factors (older age/insurance status) remained significant on multivariate analysis (increasing age at diagnosis: OR 1.03, P =.034; public insurance: OR 1.84, P = .07; and self-pay status: OR 4.49, P = .03). Conclusions No comorbidity was associated with failure to complete therapy, nor was frailty, as assessed by ECOG score. Though frailty was not significant, increasing age was, possibly reflecting negative attitudes toward chemotherapy in older populations. Insurance status also predicted failure to complete treatment, suggesting disparities in access to treatment, affected by socioeconomic factors.

scholarly journals Composition and Concentration of Serum Fatty Acids of Phospholipids Depend on Tumour Location and Disease Progression in Colorectal Patients

2018 ◽  
Vol 37 (1) ◽  
pp. 39-45 ◽  
Author(s):  
Jolanta Bugajska ◽  
Joanna Berska ◽  
Diana Hodorowicz-Zaniewska ◽  
Krystyna Sztefko
Keyword(s):  
Colorectal Cancer ◽  
Fatty Acids ◽  
Disease Progression ◽  
Cancer Patients ◽  
Distal Colon ◽  
Unsaturation Index ◽  
Serum Levels ◽  
Colorectal Tumour ◽  
Tumour Localization ◽  
Colorectal Cancer Patients

SummaryBackground: Polyunsaturated fatty acids (PUFAs) play a role in the development/progression of colon cancer. The aim of the study was to assess the relation between serum phospholipids PUFAs, colorectal tumour localization and disease progression. Methods: A total of 67 patients (18 with proximal colon, 17 with distal colon and 32 with rectal tumour localization) as well as 16 controls were studied. One year after surgery, 33 patients had disease progression. Serum levels of C16:1(n-7), C18:1(n-9), C18:3(n-3), C20:5(n-3), C22:6(n- 3), C18:2(n-6), C20:2(n-6), C20:4(n-6) fatty acids of se - rum phospholipids were quantitatively measured before surgery by gas-chromatography. Results: Significantly higher mean value of C18:2, as compared to control, has been noted only for patients with proximal (p<0.05) and distal tumour (p<0.03) localization. The lower mean level of C20:5 and unsaturation index (UI) were observed in colorectal cancer patients regardless the tumour localization, but the statistical difference was noted only for patients with proximal tumours (p<0.05, p<0.03). In patients with proximal tumours, significantly lower mean level of C20:4 and UI were noted in patients with disease progression, as compared to patients with proximal tumours without disease progression (p<0.05). Conclusion: The evaluation of PUFAs as a risk/prognostic factor in colorectal cancer patients should take into account tumour localization as a dependent variable.

Sign in / Sign up

Export Citation Format

Share Document